O4‐05–05: Race/ethnic differences in cognitive decline: Results from the health and retirement study

cognitive decline of AD patients reporting or not CVDRF was assessed using the MMSE and the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog), after 2 years of follow-up. Results: Of the 629 patients at baseline, 268 (42.6%) reported absence of CVDRF, 256 (40.7%) reported 1 CVDRF and 105 (16.7%) reported 2-3. At inclusion, hypertension was present in 44.1% of patients, hypercholesterolemia in 22.6% and diabetes in 9.4%. No statistical significant differences (p values of 0.9 for MMSE and 0.8 for ADAS-Cog) of mean cognitive declines after 2 years of follow-up were found comparing different subgroups of patients with CVDRF to the non-CVDRF group. Conclusions: Although there is evidence that CVDRF contribute to the onset of AD, these results suggest that CVDRF may not be part of the underlying processes that affect progression of AD.